Condition
AIHA - Cold Autoimmune Hemolytic Anemia
Total Trials
4
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (2)
Trial Status
Not Yet Recruiting2
Recruiting2
Clinical Trials (4)
Showing 4 of 4 trials
NCT07083960Phase 1Recruiting
OM336 in Autoimmune Cytopenias
NCT07091370Phase 1Not Yet RecruitingPrimary
Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of Therapy
NCT07019038Recruiting
National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic Anemia
NCT06847607Not ApplicableNot Yet Recruiting
A Multicenter Prospective Study of Iptacopan in the Treatment of Refractory/Relapsed Autoimmune Hemolytic Anemia (AIHA)
Showing all 4 trials